2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 857

Impact of Urate Lowering Therapy On Renal Disease Progression in Patients With Hyperuricemia
Abstract Number: 2145

Impact On Cartilage Volume Changes Over Time Of Conventional Treatment and Of Glucosamine and Chondroitin Sulfate In Knee Osteoarthritis Patients: Data From The Osteoarthritis Initiative Cohort
Abstract Number: 2696

Impaired Bacterial Clearance and An Exuberant Inflammatory Response Promote Chlamydia-Induced Reactive Arthritis In SKG Mice
Abstract Number: 2096

Impaired Shoulder-Arm Mobility and Muscle Function In Patients With Systemic Sclerosis
Abstract Number: 2425

Impaired TNFá Production By Dendritic Cells From Rheumatoid Arthritis Patients Upon Contact With Porphyromonas Gingivalis
Abstract Number: 1690

Impaired Vitamin D Receptor Signaling Upregulates Transforming Growth Factor Beta (TGFβ) Signaling In Systemic Sclerosis
Abstract Number: 189

Implementation Of a Methotrexate Self-Injection Education Video – Reducing Teaching Time While Maintaining Patient Confidence and Knowledge
Abstract Number: 2666

Implementing a Personalized Health Plan To Improve Therapeutic Outcomes In Veterans With Gout
Abstract Number: 1973

Importance Of Hand Positioning In 3D Joint Space Morphology Assessment
Abstract Number: 2137

Important Predictors Of Patient-Reported Outcomes After TKR and THR Are Not Included In Risk Models Based On Administrative Data
Abstract Number: 2529

Improved Outcomes In High Risk Lupus Pregnancies: Usefulness Of a Protocol Based Multidisciplinary Approach In Kerala, India
Abstract Number: 2154

Improvement In Clinical Symptoms After 48 Weeks Of Wearing Flexible Footwear In Osteoarthritis Of Knee: A Randomized Placebo-Controlled Study
Abstract Number: L5

Improvement in High Density Lipoprotein Function in Early Rheumatoid Arthritis Patients Treated with Methotrexate Monotherapy or Combination Therapy in the Treatment of Early Rheumatoid Arthritis Trial
Abstract Number: 2766

Improvement In Insulin Resistance Greater With The Use Of Infliximab Following Intensive Treatment Of Early Rheumatoid Arthritis
Abstract Number: 2459

Improvement In Physical Function, Health-Related Quality Of Life, and Work Productivity With Adalimumab Treatment In Non-Radiographic Axial Spondyloarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].